With 90% of the Campaign for Our Future goal reached, NHF CEO Val Bias officially launched Phase II of the campaign at the Opening Session of NHF’s 61st Annual Meeting in San Francisco, CA, on Friday, October 30, 2009.
Phase II of Campaign for Our Future: Research Is Our Future is an effort to raise $1.2 million specifically for NHF’s research program. Completion of Phase II will bring NHF to its $8.5 million campaign goal. Funds raised in this next phase will enable NHF to have a broader, more strategic research agenda, in order to accomplish the following goals:
- Increase our commitment to bleedings disorders research by expanding our research portfolio.
- Build bridges with other patient groups and similar organizations because we will be more successful when we speak collectively.
- Advocate for our community among the decision makers at the highest levels of government to influence research funding priorities.
- Undertake educational efforts designed to help the bleeding disorders community understand the purposes of genome-based diagnosis and the role it can play in improved medical management of inherited coagulation factor deficiencies.
Achievement of this campaign goal will set the stage for the creation of an annual research fund to provide a consistent, ongoing source of support to fund grants and ancillary expenses, such as travel and meeting expenses, for our grantees to promote their research.
For more information or to make a donation, please visit: www.hemophilia.org/campaignforourfuture.
The Visionary Corporate Partner and Lead Benefactor for Campaign for Our Future is Novo Nordisk. Other major sponsors include: Baxter, Principal Corporate Partner; Bayer, CSL Behring and Pfizer, Major Corporate Partners; and Grifols, Corporate Partner.